The news will intensify pressure on Pfizer Chief Executive Officer Albert Bourla, who has repeatedly pointed to the drugmaker ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant's bid to win a slice of ...

The North Texas hospital system joins over 400 other entities and a dozen state attorneys general suing over alleged ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

ESPN broadcaster Hannah Storm, who called the first broadcast of a WNBA game, spoke to PEOPLE about the extended moment women ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

Patients regularly taking Eli Lilly & Co.’s obesity shot Zepbound tend to keep the weight off for at least three years, with ...

The EPA office at RTP is facing significant cuts as DOGE continues its efforts to fire thousands of government workers across ...

Eli Lilly (LLY) stock in focus as the company projects earnings headwinds from IPR&D charges estimated at $1.57B for Q1 2025.

It’s unclear whether tariffs will influence more companies to make more drugs in the U.S. like President Donald Trump is ...